(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado - 2Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- 3Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- 4Avoid Slam: Exploring the Pickup Truck Transformation
- 5Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Father and son spending Christmas together after health scares
- Meet the rescue team behind the astronauts as Artemis II's launch approaches
- Creative Do-It-Yourself Ventures for Each Expertise Level
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- The 20 Most sultry Style of the Time
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- Bayer reports positive results for blood thinner after 2023 setback
- Vote in favor of Your Number one BWM Vehicles
